Arcus Biosciences stockholders elect four Class II directors, ratify auditor, approve say-on-pay

Arcus Biosciences, Inc.

Elected Class II directors: Dietmar Berger (85.9M for), David Lacey (86.0M), Nicole Lambert (92.7M), Johanna Mercier (85.9M); ~13.6M broker non-votes.
Ratified Ernst & Young as auditor for FY2026: 112.9M for, 4.8M against, 0.2M abstain.
Advisory say-on-pay approved: 94.9M for, 9.3M against, 29.7K abstain; 13.6M broker non-votes.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcus Biosciences, Inc. shareholders approved The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement at the 2026-06-11 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 94,920,421 9,337,368 29,741 13,573,227

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcus Biosciences, Inc. shareholders approved The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified at the 2026-06-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Proposal 1 : The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dietmar Berger, M.D., Ph.D. 85,949,508 18,338,022 13,573,227 David Lacey, M.D. 85,974,583 18,312,947 13,573,227 Nicole Lambert 92,653,341 11,634,189 13,573,227 Johanna Mercier 85,941,754 18,345,776 13,573,227

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcus Biosciences, Inc. shareholders approved The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Proposal 2 : The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 112,905,582 4,767,430 187,745

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001724521-26-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.